Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 2/20 | 0.37 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217284 | 0.88 | — | — | |
| Bromide SCHEMBL28508208 | 0.85 | NFKB1 (0.43) | QPCTQPCTLNFKB1HSD17B10CYP3A4 | |
| Pyridine SCHEMBL28304645 | 0.78 | TSHR (0.47) | TSHRNAPRTTDP1 | |
| 1-Methylimidazole SCHEMBL29178524 | 0.77 | NFKB1 (0.68) | QPCTQPCTLNFKB1HSD17B10TBXAS1 | |
| SCHEMBL10503985 | 0.72 | NFKB1 (0.46) | QPCTQPCTLNFKB1HSD17B10CYP3A4 | |
| 1-Methylimidazole SCHEMBL11368070 | 0.71 | QPCT (0.75) | TSHRNAPRTTDP1QPCTQPCTL | |
| 1-Methylimidazole SCHEMBL4991962 | 0.71 | QPCT (0.75) | TSHRNAPRTTDP1QPCTQPCTL | |
| 1-Methylimidazole SCHEMBL28150706 | 0.70 | QPCT (0.71) | TSHRNAPRTTDP1QPCTQPCTL | |
| 1-Methylimidazole SCHEMBL3328112 | 0.70 | QPCT (0.71) | TSHRNAPRTTDP1QPCTQPCTL | |
| Pyridine SCHEMBL27779675 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111900477-A | High-voltage lithium ion battery electrolyte film-forming additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-11-06 | — | — | CN | claimed |
| US-12636301-B2 | 5′-modified carbocyclic ribonucleotide derivatives and methods of use | SANEGENE BIO USA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4676497-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CELL DEATH INDUCING DFFA LIKE EFFECTOR B (CIDEB) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4638742-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-29 | — | — | EP | disclosed |
| EP-4630556-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING 3 (PNPLA3) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025108284-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SODIUM VOLTAGE-GATED CHANNEL ALPHA SUBUNIT 9 (SCN9A) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025040097-A1 | SIRNA TARGETING ANGPTL4, AND CONJUGATE AND USE THEREOF | 成都先衍生物技术有限公司 | 2025-02-27 | — | — | WO | disclosed |
| EP-4482845-A1 | 5'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USE | Sanegene Bio USA Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118922431-A | 5' -Modified carbocyclic ribonucleotide derivatives and methods of use | 美国圣因生物股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024227458-A2 | SIRNA TARGETING AGT GENE EXPRESSION AND CONJUGATE AND USE THEREOF | 成都先衍生物技术有限公司 | 2024-11-07 | — | — | WO | disclosed |
| EP-3786623-A1 | OPTIMIZED ANALYTE DERIVATIZATION FOR SYNERGISTIC APPLICATION WITH CRYSTAL SPONGE METHOD | Merck Patent GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| CN-111900477-A | High-voltage lithium ion battery electrolyte film-forming additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-11-06 | — | — | CN | disclosed |
| US-6825173-B2 | ANTIDIABETIC AGENTS; UROGENITAL DISORDERS | CORNELL RESEARCH FOUNDATION, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030130208-A1 | Preparation of fagopyritols and uses therefor | OBENDORF RALPH L (US) | 2003-07-10 | — | — | US | disclosed |
| US-6492341-B1 | Preparation of fagopyritols and uses therefor | CORNELL RESEARCH FOUNDATION, INC. | 2002-12-10 | — | — | US | disclosed |
| WO-2001089532-A1 | PREPARATION OF FAGOPYRITOLS AND USES THEREFOR | CORNELL RESEARCH FOUNDATION, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-5633356-A | RADIOACTIVE INTERMEDIATE METABOLITE FOR USE IN DIAGNOSTIC TESTING | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-27 | — | — | US | disclosed |
| US-5623063-A | USING CARBON ISOTOPE-LABELLED GLUCOSE AS STARTING MATERIAL | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| US-5618734-A | USING A LABELLED CARBON COMPOUND AS AN INTERNAL STANDARD; USEFUL IN DIAGNOSING DIABETES AND KIDNEY DISEASES | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-04-08 | — | — | US | disclosed |
| EP-0645625-A1 | 3-Deoxyglucosone derivatives and method for determining the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130208-A1 | Preparation of fagopyritols and uses therefor | FBP1, ALDOA, PFKFB1 | TSHR 3460/4885NAPRT 298/4885TDP1 3851/4885 |
| US-12636301-B2 | 5′-modified carbocyclic ribonucleotide derivatives and methods of use | NSUN2, RNASE1, RNASEL | TSHR 258/4885NAPRT 2214/4885TDP1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.